HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Roundup: No GRAS For PHOs, Pfizer Expands In China, MusclePharm Targets Over-40 Consumers

This article was originally published in The Tan Sheet

Executive Summary

Partially hydrogenated oils lose GRAS; Pfizer expands consumer product output in China; MusclePharm adding direct sales; U.K. requires registration, logo for online sales; and more news in brief.

You may also be interested in...



CFSAN Priorities: Industry & Consumer Groups Weigh In On NDIs And More

FDA should accept safety findings from outside expert panels when reviewing new dietary ingredient notifications, CHPA says in Aug. 25 comments on CFSAN priorities

US Proposed OTC Hearing Aid Rule Inspired Soundly Founder To ‘Make This Process Easier’

In recent interview, CEO Blake Cadwell talked about Soundly’s business model and outlook for hearing aid marketplace after FDA's pending publication of rule aiming to make the devices more accessible. Firm since June has offered online testing and advice for customers about hearing aids best suited for their needs.

Revlon Gains $1.4Bn Financing From Subsidiaries, Appoints Interim CFO Amid Bankruptcy Fallout

Revlon approved for $1.4bn debtor-in-possession financing from BrandCo Lenders, a group of operating subsidiaries formed in capital structure changes which owns much of Revlon’s intellectual property. Firm appoints interim CFO to set course for debt restructuring.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS123726

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel